Update on the management of inflammatory bowel disease: specific role of adalimumab
Luisa Guidi, Daniela Pugliese, Alessandro ArmuzziInternal Medicine and Gastroenterology, Complesso Integrato Columbus, Università Cattolica del Sacro Cuore, Rome, ItalyAbstract: Anti-tumor necrosis factor alpha (TNF-a) medications are a class of biologics employed in the treatment of...
Main Authors: | Guidi L, Pugliese D, Armuzzi A |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2011-07-01
|
Series: | Clinical and Experimental Gastroenterology |
Online Access: | http://www.dovepress.com/update-on-the-management-of-inflammatory-bowel-disease-specific-role-o-a7879 |
Similar Items
-
Predictors and Early Markers of Response to Biological Therapies in Inflammatory Bowel Diseases
by: Giuseppe Privitera, et al.
Published: (2021-02-01) -
Efficacy and Safety of Adalimumab Biosimilar GP2017 in Patients with Inflammatory Bowel Disease
by: Marta Vernero, et al.
Published: (2023-10-01) -
Adalimumab induced psoriasis during the treatment of inflammatory bowel disease – case report
by: Edyta Lelonek, et al.
Published: (2015-09-01) -
Adalimumab Biosimilar in Pediatric Inflammatory Bowel Disease: A Retrospective Study from the Sicilian Network for Inflammatory Bowel Disease (SN-IBD)
by: Valeria Dipasquale, et al.
Published: (2024-02-01) -
Genetics of inflammatory bowel disease--an update.
by: van Heel, D, et al.
Published: (2001)